How to Buy Aclaris Therapeutics, Inc. (ACRS) Stock

Where to buy ACRS

13 brokers in our matrix offer ACRS. Verify availability and current fees with each broker before trading.

Broker	Commission	Fractional	Extended	Overnight	Options	OTC access
Charles Schwab (thinkorswim)	$0	Schwab Stock Slices, S&P 500 only, ≥ $5/slice, up to 30 at once		~1,130	$0.65	Most (3/5)
E*TRADE (Morgan Stanley)	$0 listed			~20	$0.65	Most (4/5)
Fidelity	$0	Stocks by the Slice, 7,000+ stocks/ETFs, from $1			$0.65	Partial (2+0)
Firstrade	$0	~4,000+ tickers, ≥ $5		~1,200	$0	Most (4/5)
Interactive Brokers	$0 (Lite) / per-share (Pro)			~10,000	per-contract pricing	Full
Merrill Edge	$0				$0.65	Most (3/5)
Moomoo	$0				$0	Limited only
Public.com	$0				rebate model	Limited only
Robinhood	$0	≥ $1 stocks, market cap ≥ $25M		~1,134	$0	None
SoFi Active Investing	$0				$0	Partial (1+2)
tastytrade	$0 stocks				$1.00 open, $0 close (capped at $10 per leg)	Limited only
TradeStation	$0 listed				$0.50 / $0.60	Most (4/5)
Webull	$0				$0	Limited only

24-Hour / Overnight trading

ACRS may be eligible for overnight trading via Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), Webull, Moomoo, Firstrade. Each broker maintains its own eligibility list — confirm before placing an order.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company. It focuses on developing novel drug candidates for immuno-inflammatory diseases using its proprietary KINect drug discovery platform. The company's pipeline consists of the following key product candidates: Bosakitug (ATI-045), an investigational, novel, humanized anti-TSLP monoclonal antibody being developed for patients with severe asthma, COPD, and chronic rhinosinusitis with nasal polyps; ATI-2138, being developed for the potential treatment of T cell-mediated autoimmune diseases; and ATI-052 and ATI-9494. Additionally, it has an investigational product candidate, Lepzacitinib (ATI-1777), which is being focused upon as a potential treatment for atopic dermatitis and potentially other dermatologic conditions.

Sector

PHARMACEUTICAL PREPARATIONS

Employees

73

Headquarters

WAYNE, PA

Listed

2015-10-07

Market cap

$681.56M

Frequently asked

Where can I buy Aclaris Therapeutics, Inc. (ACRS)?

ACRS is offered by 13 brokers in our matrix, including Charles Schwab (thinkorswim), E*TRADE (Morgan Stanley), Fidelity, Firstrade, Interactive Brokers. Compare commissions, fractional eligibility, and overnight availability in the broker matrix above.

Can I buy ACRS after hours or overnight?

Yes. ACRS is on the 24-hour eligibility list for Charles Schwab (thinkorswim), Interactive Brokers, Robinhood, E*TRADE (Morgan Stanley), and others. Overnight sessions route through ATSs with wider spreads and limit-orders only.

Does Robinhood offer ACRS?

Yes. Robinhood offers ACRS as a regular exchange-listed security.

Does Fidelity offer ACRS?

Yes. Fidelity offers ACRS as a regular exchange-listed security.

Does Webull offer ACRS?

Yes. Webull offers ACRS as a regular exchange-listed security.

Is ACRS optionable?

Yes. ACRS has listed options contracts. Per-contract pricing varies by broker — see the Options column in the matrix.

Is there a tokenized version of ACRS?

Not in our current dataset. The tokenized stock universe (Kraken xStocks, Binance Alpha/Ondo, Robinhood EU, Hyperliquid HIP-3) is expanding quickly — we refresh quarterly.

Can I buy a fractional share of ACRS?

Yes. Multiple brokers in the matrix support fractional shares for ACRS — see the Fractional column above for per-broker eligibility and minimums.